.Nature Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin led to boosted progression-free and also total survival, triggering FDA commendation as well as a new procedure choice for patients.